3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Hepatocellular
5
Leukemia, Myeloid, Acute
3
Uveal Melanoma
2
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Leiomyosarcoma
1
HER2 Negative Metastatic Breast Cancer
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Pemetrexed
13
Cisplatin
12
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cyclophosphamide
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
fludarabine
3
defactinib
3
amatuximab
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
tremelimumab
1
tazemetostat
1
osimertinib
1
napabucasin
1
enzalutamide
1
bemcentinib
1
abemaciclib
1
VS-5584
1
Trabectedin
1
Thiostrepton
1
Safety
1
Panobinostat
1
Monatide (IMS 3015)
1
Midazolam
1
Letrozole
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma, Malignant
×
ADI PEG20
×
Clear all
NCT02709512
2023-10-04
ATOMIC
Polaris Group
Phase 2/3
Completed
249 enrolled
17 charts